1. Beyond First Line CDK4/6 Inhibitors (CDK4/6i) and Aromatase Inhibitors (AI) in Patients with Oestrogen Receptor Positive Metastatic Breast Cancer (ER+ MBC): The Guy's Cancer Centre Experience. Issue 4 (April 2022) Authors: Gousis, C.; Michoglou, K.; Lowe, H.; Kapiris, M.; Angelis, V. Journal: Clinical oncology Issue: Volume 34:Issue 4(2022) Page Start: e178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Systemic therapies post progression on CDK4/6 inhibitors in patients with oestrogen receptor positive metastatic breast cancer: Real world data from Guy's Cancer Centre. (November 2022) Authors: Gousis, C.; Michoglou, K.; Lowe, H.; Akay, M.; Kapiris, M.; Angelis, V. Journal: European journal of cancer Issue: Volume 175(2022)Supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗